Concepedia

Author

David Kan

Bristol-Myers Squibb (United States)

Also Known As

D. Kan, David Kan

64

Publications

2.9K

Citations

21

H-Index

48

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Germany)Genesys (United States)Howard Hughes Medical InstituteUniversity of California, San Francisco
DK

About

David Kan is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

11

1.7K

2

Cell Biology

5

5

176

3

Immunology

3

3

97

4

Health Sciences

2

2

75

5

Gastroenterology

1

1

98

David Kan

×

23

Publications

2.9K

Citations

21

H-Index

YearCitations

Discovery of <i>N</i>-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

Louis J. Lombardo, Francis Y. Lee, Ping Chen,

Journal of Medicinal Chemistry

2004

1.3K

Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site

Jenny Boström, Shang‐Fan Yu, David Kan,

Science

2009

362

Antibody targeting of E3 ubiquitin ligases for receptor degradation

Hadir Marei, Wen‐Ting K. Tsai, Yee-Seir Kee,

Nature

2022

230

Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure

Feng Luo, Zheng Yang, Amy Camuso,

Clinical Cancer Research

2006

149

Disruption of IRE1α through its kinase domain attenuates multiple myeloma

Jonathan M. Harnoss, Adrien Le Thomas, Anna Shemorry,

Proceedings of the National Academy of Sciences

2019

112

Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index &lt; 1

Yu Zhong, Paula Katavolos, Tien‐Trung Nguyen,

Toxicologic Pathology

2015

98

Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft

Feng Luo, Zheng Yang, Huijing Dong,

Cancer Chemotherapy and Pharmacology

2005

85

IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment

Jonathan M. Harnoss, Adrien Le Thomas, Mike Reichelt,

Cancer Research

2020

83

Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels

Robert A. Wild, Krista Fager, Christine Flefleh,

Molecular Cancer Therapeutics

2006

62

Synergistic Antitumor Activity of Ixabepilone (BMS-247550) Plus Bevacizumab in Multiple <i>In vivo</i> Tumor Models

Francis Y. F. Lee, Kelly L. Covello, Stephen Castaneda,

Clinical Cancer Research

2008

44

Page 1